ABSTRACT: Proponents of the ‘Threshold View’ have held that to believe a proposition is to be sufficiently confident of the proposition’s truth, but that there is no sharp cutoff between degrees of confidence that constitute belief and degrees of confidence that do not. Brian Weatherson has objected that no plausible account of vagueness can support this view. In this paper, I reply to Weatherson’s objection. Along the way, I identify a way in which one might hope to maintain the Threshold (...) View without a fuzzy threshold, and I reformulate the Threshold View to accommodate fuzzy thresholds without begging substantive questions about vagueness. -/- RÉSUMÉ : D’après la «théorie du seuil», croire une proposition, c’est être suffisamment sûr de la vérité de cette proposition, bien qu’il n’y ait pas de limite nette entre les degrés de certitude qui constituent une croyance et ceux qui n’en constituent pas une. Pour Brian Weatherson, cette thèse ne peut être appuyée sur aucune théorie plausible du vague. Dans cet article, je réponds à Weatherson et propose une reformulation de la théorie du seuil qui contient des seuils flous sans engager des présupposés controversables en théorie du vague. J’identifie également une façon de conserver la théorie sans avoir un seuil flou. (shrink)

I defend Conciliationism: rationality requires belief revision of epistemic peers who find themselves in disagreement and lack dispute-independent reason to suspect each other of error. (Kelly 2010) argues that Conciliationists are committed to the Uniqueness Thesis: a given body of evidence rationalizes a unique degree of confidence for a given proposition. (Ballantyne & Coffman 2012) cogently critique Kelly's argument and propose an improved version. I contend that their version of the argument is unsound, and I offer some friendly amendments. But (...) I show that even this amended argument threatens only extreme versions of Conciliationism. (shrink)

With over 2 billion people lacking medicines for treatable diseases and 14 million people dying annually from infectious disease, there is undeniable need for increased access to medicines. There has been an increasing trend to benchmark the pharmaceutical industry on their corporate social responsibility (CSR) performance in access to medicines. Benchmarking creates a competitive inter-business environment and acts as incentive for improving CSR. This article investigates the corporate feedback discourses pharmaceutical companies make in response to criticisms from benchmarking reports. It (...) determines whether these responses are part of a healthy process in increasing access to medicines or a barrier to improvement. A qualitative analysis on the feedback the industry provided was performed, and the responses seen in these statements were grouped by analysing the language used, the ideas portrayed and attitudes of the companies. Increasing transparency through benchmarking is a powerful tool which reveals the industry's shortfalls to the public, affects the decisions of socially responsible investors, and is a risk to their financial bottom line. This article demonstrates the importance of benchmarking and transparency in creating inter-business competition and the translation of these responses to actual access to medicine practices. (shrink)

With over 2 billion people lacking medicines for treatable diseases and 14 million people dying annually from infectious disease, there is undeniable need for increased access to medicines. There has been an increasing trend to benchmark the pharmaceutical industry on their corporate social responsibility (CSR) performance in access to medicines. Benchmarking creates a competitive inter-business environment and acts as incentive for improving CSR. This article investigates the corporate feedback discourses pharmaceutical companies make in response to criticisms from benchmarking reports. It (...) determines whether these responses are part of a healthy process in increasing access to medicines or a barrier to improvement. A qualitative analysis on the feedback the industry provided was performed, and the responses seen in these statements were grouped by analysing the language used, the ideas portrayed and atti- tudes of the companies. Increasing transparency through benchmarking is a powerful tool which reveals the industry’s shortfalls to the public, affects the decisions of socially responsible investors, and is a risk to their financial bottom line. This article demonstrates the importance of benchmarking and transparency in creating inter-business competition and the translation of these responses to actual access to medicine practices. (shrink)